As human epidermal growth factor receptor 2 (HER2) is upregulated on approximately one-third of B-ALL samples, a phase 2 study administered trastuzumab to 15 patients with HER2-positive R/R B-ALL; although treatment was well-tolerated, no CRs were observed [142]. Here, ERBB2 is linked to acute lymphoblastic leukemia.